^{1. Yap F, et al. Growth assessment and monitoring during childhood. Ann Acad Med Singap. 2018;47:149-55.}

^{2. Polidori N, et al. Deciphering short stature in children. Ann Pediatr Endocrinol Metab. 2020;25:69-79.}

^{3. Rogol AD, et al. Growth and pubertal development in children and adolescents: effects of diet and physical activity. Am J Clin Nutr. 2000;72(suppl):521S-8S.}

^{4. Khadilkar V, et al. Growth charts: A diagnostic tool. Indian J Endocr Metab. 2011;15:166-71.}

^{5. Haymond M, et al. Early recognition of growth abnormalities permitting early intervention. Acta Paediatr. 2013;102:787-96.}

^{6. Perkins JM, et al. Adult height, nutrition, and population health. Nutr Rev. 2016;74:149-65.}

^{7. Rogol AD, et al. Etiologies and early diagnosis of short stature and growth failure in children and adolescents. J Pediatr. 2014;164:S1-S14.}

^{8. Vilcins D, et al. Environmental risk factors associated with child stunting: a systematic review of the literature. Ann Glob Health. 2018;84:551-62.}

^{9. Stanhope R, et al. Failure to grow: lack of food or lack of love? Prof Care Mother Child. 1994;4:234-7.}

^{10. Rogol AD. Emotional deprivation in children: growth faltering and reversible hypopituitarism. Front Endocrinol. 2020;11:596144.}

^{11. Matfin G, et al. Chapter 42: Disorders of endocrine control of growth and metabolism. In Porth CM (editor). Pathophysiology: Concepts of Altered Health States, 7th ed. Philadelphia; Lippincott Williams & Wilkins: 2005.}

^{12. Lui JC, et al. Cartilage-targeted IGF-1 treatment to promote longitudinal bone growth. Molecular Ther. 2019;27:673-80.}

^{13. Barstow C, et al. Evaluation of short and tall stature in children. Am Fam Physician. 2015;92:43-50.}

^{14. Reh CS, et al. Somatotropin in the treatment of growth hormone deficiency and Turner syndrome in pediatric patients: a review. Clin Pharmacol. 2010;2:111-22.}

^{15. NICE. Human growth hormone (somatropin) for the treatment of growth failure in children. Technology appraisal guidance. Published 26 May 2010. Available at: https://www.nice.org.uk/guidance/ta188. Accessed 29 July 2020.}

^{16. Growth Hormone Research Society. Consensus guidelines for the diagnosis and treatment of growth hormone (GH) deficiency in childhood and adolescence: summary statement of the GH Research Society. J Clin Endocrinol Metab. 2000;85:3990-3.}

^{17. Hatfield NT. Introductory Maternal & Pediatric Nursing. 3rd edition. USA: Wolters Kluwer Health; 2014.}

^{18. Barzilai R, et al. Small for gestational age: the familial perspective. J Matern Fetal Neonatal Med. 2020;1-5.}

^{19. Royal College of Obstetrics and Gynaecology. The investigation and management of the small– for–gestational–age fetus. Green-top guideline no. 31. 2nd edition. February 2013. Minor revisions January 2014. Available at: https://www.rcog.org.uk/media/t3lmjhnl/gtg_31.pdf. Accessed 29 July 2022.}

^{20. Clayton PE, et al. Management of the child born small for gestational age through to adulthood: a consensus statement of the International Societies of Pediatric Endocrinology and the Growth Hormone Research Society. J Clin Endocrinol Metab. 2007;92:804-10.}

^{21. Tan KBL, et al. Pattern of Turner syndrome in Singapore (1999-2004). Singapore Med J. 2009;50:587.}

^{22. Thayalan K, et al. Turner syndrome – The clinical spectrum and management dilemmas. Australas J Ultrasound Med. 2018;21:219-26.}

^{23. Morgan T. Turner syndrome: diagnosis and management. Am Fam Physician. 2007;76(3):405-410.}

^{24. McCandless S, et al. Clinical report – health supervision for children with Prader-Willi syndrome. Pediatrics. 2011;127:195-204.}

^{25. Butler MG, et al. Prader-Willi syndrome - clinical genetics, diagnosis and treatment approaches: an update. Curr Pediatr Rev. 2019;15:207-44.}

^{26. Cassidy SB, et al. Prader Willi syndrome. Genet Med. 2012:14:10-26.}

^{27. Agency for Care Effectiveness. Somatropin for the treatment of growth failure in children. Updated 3 May 2017. Available at: https://www.ace-hta.gov.sg/healthcare-professionals/ace technology-guidances/details/somatropin-for-the-treatment-of-growth-failure-in-children. Accessed 25 July 2022.}

^{28. Chatelain P, et al. Growth hormone therapy for short children born small for gestational age. Horm Res. 2007;68:300-9.}

^{29. Health Sciences Authority. Register of therapeutic products. Available at: www.hsa.gov.sg. Accessed 29 July 2022.}

^{30. George B, et al. Shared decision making and patient choice for growth hormone therapy: current perspectives. Res Rep Endocr Disord. 2016:6.}

^{31. Tanaka T, et al. Patient preferences for growth hormone treatment in Japanese children. Pediatr Int. 2021;63:1185-91.}

^{32. Rohrer TR, et al. Growth hormone delivery devices: current features and potential for enhanced treatment adherence. Expert Opin Drug Deliv. 2017;14:1253-64.}

^{33. MIMS. SciTropin A. Consumer Medicine Information. December 2020. Available at: https://www.nps.org.au/assets/medicines/83d30dcb-1f14-4d49-836b-a53300ff22d1.pdf. Accessed 29 July 2022.}

^{34. Press Release. SciGen receives approval from Australian Register of Therapeutic Goods, for Nemera’s reusable pen injector, for its human growth hormone. 17 March 2022. Available at: https://www.nemera.net/wp-content/uploads/2022/03/220317_Nemera_press-release_SciGen-approval-from-ARTG.pdf. Accessed 29 July 2022.}

^{35. Kirk JMW, et al. Persistence of neurological damage induced by dietary deficiency in rats. Food Chem Toxicol. 2018;111:280-9.}

^{36. Donabedian S, et al. A physician's review of growth hormone secretagogues. J Eval Clin Pract. 2015;21:635-8.}

^{37. Aguiar-Oliveira MH, et al. Growth hormone receptor deficiency in humans. Biomolecules. 2020;10:1025.}

^{38. Hsiao HP, et al. Next-generation sequencing for diagnosing growth disorders: adding value to the diagnosis. Genes. 2020;11:1365.}

^{39. Meazza C, et al. Combined pituitary hormone deficiency: current and future perspectives. Int J Mol Sci. 2020;21:1286.}

^{40. Cohen P. Recent advances in the molecular genetics of growth hormone (GH) deficiency. Endocr Rev. 2020;41:bnaa012.}

^{41. Saldarriaga W, et al. A novel mutation in GH1 gene in a Colombian patient with isolated growth hormone deficiency. Int J Mol Sci. 2020;21:2781.}

^{42. Sakalihasan N, et al. Growth hormone therapy in children and adolescents: a review of clinical guidelines. Horm Res Paediatr. 2020;93:169-82.}

^{43. Hokken-Koelega ACS, et al. Growth hormone therapy in children born small for gestational age: 5-year results of a randomized, double-blind, dose-response trial. J Clin Endocrinol Metab. 2005;90:2816-23.}

^{44. Ranke MB, et al. Growth hormone treatment in children. Pediatric Endocrinology. Karger Publishers; 2010:240-58.}

^{45. Sanchez Ramos L, et al. Unveiling the critical events contributing to intrauterine growth restriction. Reproduction. 2020;160:R1-R12.}

^{46. De Curtis M, et al. Growth hormone therapy for Prader-Willi syndrome: challenges and solutions. Ther Clin Risk Manag. 2016;12:873-81.}

^{47. Weiler RM, et al. Short stature: a symptom with many possible causes. Endocrinol Diabetes Metab Case Rep. 2015;2015:150049.}

^{48. Cianfarani S, et al. Effect of growth hormone treatment on children with idiopathic short stature. Horm Res Paediatr. 2011;76(Suppl 3):26-8.}

^{49. Rao E, et al. Genetic disorders of growth hormone action. Horm Res Paediatr. 2011;76(Suppl 3):19-22.}

^{50. Tatsi C, et al. Genetic causes of growth hormone deficiency. J Pediatr Endocrinol Metab. 2018;31:247-58.}

^{51. Fuqua JS, et al. Diagnostic approach to children with short stature. Curr Opin Pediatr. 2021;33:497-503.}

^{52. Lanfranco F, et al. Testosterone and gonadotropin-releasing hormone analogues in adult men with hypogonadotropic hypogonadism: effects on body composition and muscle function. J Endocrinol Invest. 2015;38:1111-20.}

^{53. Walker JL, et al. Diagnosing and managing Turner syndrome in children and adolescents. Curr Opin Pediatr. 2016;28:529-35.}

^{54. Bergadá I, et al. A case of female hypergonadotropic hypogonadism due to an inherited aromatase excess syndrome. J Clin Endocrinol Metab. 2015;100:4394-7.}

^{55. Coutant R, et al. Growth and adult height in GH-treated children with nonacquired GH deficiency and idiopathic short stature: the influence of pituitary magnetic resonance imaging findings. J Clin Endocrinol Metab. 2012;97:1907-14.}

^{56. Deodati A, et al. Long-term safety of growth hormone therapy: state of the art and future perspectives. Minerva Endocrinol. 2020;45:149-65.}

^{57. Stephure DK, et al. Canadian consensus guidelines for the diagnosis and management of Turner syndrome in children. Can Med Assoc J. 2003;168:445-52.}

^{58. Woelfle J, et al. Early detection of growth hormone deficiency: clinical relevance and bioeconomic aspects. Growth Horm IGF Res. 2020;51:101-7.}

^{59. Ranke MB, et al. Genetic analyses and treatment perspectives in short children born small for gestational age. Pediatr Res. 2019;85:920-8.}

^{60. Tauber M, et al. Management of short children born small for gestational age through to adulthood: a consensus statement of the International Societies of Pediatric Endocrinology and the Growth Hormone Research Society. J Clin Endocrinol Metab. 2007;92:804-10.}

^{61. Marzullo P, et al. Childhood and adult obesity: different predisposition genetic and clinical aspects. J Clin Res Pediatr Endocrinol. 2021;13(Suppl 1):13-8.}

^{62. Meazza C, et al. The effects of obesity on the musculoskeletal system and consequences for bone health. J Clin Res Pediatr Endocrinol. 2020;12(Suppl 1):58-68.}

^{63. Hung A, et al. Excess body fat accumulation in children and adolescents: causes, consequences, prevention and treatment. Obes Rev. 2021;22(Suppl 1):e13085.}

^{64. Puder JJ, et al. Clinical practice guideline on pediatric obesity. Swiss Med Wkly. 2019;149:w20135.}

^{65. Kweh CK, et al. Genetic and epigenetic insights into fetal alcohol spectrum disorders. Biomolecules. 2020;10:1551.}

^{66. Chang YM, et al. Fetal growth restriction: current perspectives. J Chin Med Assoc. 2020;83:745-54.}